Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

JCPyV T-Antigen Activation of the Anti-Apoptotic Survivin Promoter-Its Role in the Development of Progressive Multifocal Leukoencephalopathy.

Tytuł:
JCPyV T-Antigen Activation of the Anti-Apoptotic Survivin Promoter-Its Role in the Development of Progressive Multifocal Leukoencephalopathy.
Autorzy:
Del Valle L; Neurological Cancer Research, Stanley S. Scott Cancer Center, Departments of Medicine & Pathology, Louisiana State University Health, New Orleans, LA 70112, USA.
Sweet T; Infectious Diseases & AIDS Epidemiology, Department of Epidemiology & Biostatistics, Drexel University Dornsife School of Public Health, Philadelphia, PA 19104, USA.
Parker-Struckhoff A; Neurological Cancer Research, Stanley S. Scott Cancer Center, Louisiana State University Health, New Orleans, LA 70112, USA.
Perez-Liz G; A.J. Drexel Autism Institute, Drexel University, Philadelphia, PA 19104, USA.
Piña-Oviedo S; Department of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Źródło:
Viruses [Viruses] 2020 Nov 03; Vol. 12 (11). Date of Electronic Publication: 2020 Nov 03.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI
MeSH Terms:
Apoptosis*
Promoter Regions, Genetic*
Antigens, Viral, Tumor/*genetics
JC Virus/*genetics
Survivin/*genetics
Adult ; Aged ; Animals ; Antigens, Viral, Tumor/immunology ; Astrocytes/virology ; Caspases/immunology ; Cell Line, Tumor ; Cells, Cultured ; Child ; DNA Fragmentation ; Female ; Humans ; JC Virus/immunology ; JC Virus/pathogenicity ; Leukoencephalopathy, Progressive Multifocal ; Male ; Mice ; Middle Aged ; Oligodendroglia/virology ; Paraffin Embedding ; Survivin/immunology
References:
J Med Virol. 2005 Nov;77(3):374-81. (PMID: 16173017)
J Gen Virol. 2017 Jun;98(6):1159-1160. (PMID: 28640744)
Nature. 1998 Dec 10;396(6711):580-4. (PMID: 9859993)
J Biol Chem. 2008 Feb 8;283(6):3289-96. (PMID: 18057009)
Curr Top Microbiol Immunol. 2005;289:79-111. (PMID: 15791952)
Brain. 1958 Mar;81(1):93-111. (PMID: 13523006)
J Virol. 2004 May;78(9):4884-91. (PMID: 15078969)
Int J Cancer. 2008 Mar 15;122(6):1278-87. (PMID: 18027854)
J Neurovirol. 2000 May;6 Suppl 1:S38-43. (PMID: 10871764)
Neurosci Lett. 2007 Jun 13;420(2):144-9. (PMID: 17531383)
Virus Res. 2006 Nov;121(2):144-51. (PMID: 16814422)
Neurosci Lett. 2002 Jul 5;326(3):175-8. (PMID: 12095650)
J Biol Chem. 1998 May 1;273(18):11177-82. (PMID: 9556606)
Virology. 1973 Apr;52(2):456-67. (PMID: 4705382)
Neuroimaging Clin N Am. 2008 Feb;18(1):19-39; vii. (PMID: 18319153)
Oncogene. 1999 Jan 7;18(1):39-46. (PMID: 9926918)
Front Oncol. 2019 Aug 08;9:711. (PMID: 31440465)
J Cell Biochem. 1997 Nov 1;67(2):223-30. (PMID: 9328827)
Brain Res Brain Res Rev. 2005 Dec 1;50(1):69-85. (PMID: 15982744)
J Virol. 1993 Nov;67(11):6689-97. (PMID: 8411371)
Nucleic Acids Res. 2007;35(7):2390-402. (PMID: 17392340)
Oncogene. 2006 Jun 1;25(23):3296-306. (PMID: 16462771)
J Child Neurol. 2002 Oct;17(10):725-30. (PMID: 12546425)
Mol Cell Biol. 2007 Nov;27(21):7703-17. (PMID: 17785436)
Curr Top Microbiol Immunol. 2005;289:25-56. (PMID: 15791950)
Cancer Res. 2007 Jul 1;67(13):5999-6002. (PMID: 17616652)
Am J Pathol. 2003 Oct;163(4):1379-93. (PMID: 14507646)
Apoptosis. 2003 Jan;8(1):71-9. (PMID: 12510154)
Am J Pathol. 2006 Jul;169(1):1-11. (PMID: 16816356)
J Neurovirol. 2004;10 Suppl 1:102-7. (PMID: 14982747)
Biochem J. 1999 Dec 1;344 Pt 2:305-11. (PMID: 10567210)
Int J Cancer. 2005 Jul 20;115(6):967-74. (PMID: 15729715)
J Virol. 2003 Oct;77(19):10638-44. (PMID: 12970448)
J Natl Cancer Inst. 2002 Apr 3;94(7):522-8. (PMID: 11929953)
J Gen Virol. 2006 Feb;87(Pt 2):287-294. (PMID: 16432013)
J Biol Chem. 2006 Sep 8;281(36):25903-14. (PMID: 16847054)
Cancer Res. 2008 Mar 1;68(5):1427-35. (PMID: 18316606)
Neuropathol Appl Neurobiol. 1997 Jun;23(3):218-24. (PMID: 9223131)
Nat Rev Cancer. 2003 Jan;3(1):46-54. (PMID: 12509766)
J Neurosci. 2002 May 15;22(10):4015-24. (PMID: 12019321)
Cancer Res. 2008 Oct 1;68(19):7923-31. (PMID: 18829549)
BMC Cancer. 2008 May 02;8:129. (PMID: 18454859)
Oncogene. 2003 Nov 24;22(53):8581-9. (PMID: 14634620)
J Neuropathol Exp Neurol. 2008 Aug;67(8):729-40. (PMID: 18648329)
J Neurovirol. 1995 Mar;1(1):5-18. (PMID: 9222338)
J Infect Dis. 2002 Dec 1;186(11):1547-57. (PMID: 12447729)
J Biol Chem. 1989 Sep 25;264(27):16160-4. (PMID: 2777758)
Drug Saf. 2010 Nov 1;33(11):969-83. (PMID: 20925435)
Ultrastruct Pathol. 1993 Nov-Dec;17(6):599-609. (PMID: 8122326)
Int J Cancer. 2005 Apr 20;114(4):509-12. (PMID: 15578717)
Am J Pathol. 2007 Apr;170(4):1291-304. (PMID: 17392168)
Annu Rev Med. 2010;61:35-47. (PMID: 19719397)
Oncogene. 2007 Dec 6;26(55):7628-36. (PMID: 17637758)
EMBO J. 2003 Jun 2;22(11):2729-40. (PMID: 12773388)
Oncogene. 2002 Apr 18;21(17):2613-22. (PMID: 11965534)
Exp Hematol. 2007 Jun;35(6):957-66. (PMID: 17533050)
Lancet. 2006 Aug 5;368(9534):489-504. (PMID: 16890836)
J Biol Chem. 2002 Feb 1;277(5):3247-57. (PMID: 11714700)
Front Biosci. 2006 Jan 01;11:718-32. (PMID: 16146764)
Grant Information:
P30 GM114732 United States GM NIGMS NIH HHS; R01 NS055644 United States NS NINDS NIH HHS; P20 GM21288 United States GM NIGMS NIH HHS
Contributed Indexing:
Keywords: ChIP assay; JC polyomavirus; JCPyV; T-antigen; progressive multifocal leukoencephalopathy; proximity ligation assay; survivin
Substance Nomenclature:
0 (Antigens, Viral, Tumor)
0 (Survivin)
EC 3.4.22.- (Caspases)
Entry Date(s):
Date Created: 20201106 Date Completed: 20210305 Latest Revision: 20210305
Update Code:
20240105
PubMed Central ID:
PMC7693140
DOI:
10.3390/v12111253
PMID:
33153187
Czasopismo naukowe
Progressive Multifocal Leukoencephalopathy (PML) is a fatal demyelinating disease of the CNS, resulting from the lytic infection of oligodendrocytes by the human neurotropic polyomavirus JC (JCPyV), typically associated with severe immunocompromised states and, in recent years, with the use of immunotherapies. Apoptosis is a homeostatic mechanism to dispose of senescent or damaged cells, including virally infected cells, triggered in the vast majority of viral infections of the brain. Previously, we showed upregulation of the normally dormant anti-apoptotic protein Survivin in cases of PML, which-in vitro-resulted in protection from apoptosis in JCPyV-infected primary cultures of astrocytes and oligodendrocytes. In the present study, we first demonstrate the absence of apoptotic DNA fragmentation and the lack of caspase activity in 16 cases of PML. We also identified the viral protein large T-Antigen as being responsible for the activation of the Survivin promoter. Chromatin Immunoprecipitation assay shows a direct binding between T-Antigen and the Survivin promoter DNA. Finally, we have identified the specific region of T-Antigen, spanning from amino acids 266 and 688, which binds to Survivin and translocates it to the nucleus, providing evidence of a mechanism that results in the efficient replication of JCPyV and a potential target for novel therapies.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies